当前位置：
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-09-05 , DOI: 10.1038/s41408-024-01134-3 Ricardo D Parrondo 1 , Betsy R LaPlant 2 , Jamie Elliott 1 , Andre Fernandez 1 , Caitlin J Flott 1 , Diedre Arrington 1 , Dustin Chapin 1 , Jade Brown 1 , Saurav Das 1 , Vivek Roy 1 , Asher A Chanan-Khan 1, 3 , Sikander Ailawadhi 1, 3
中文翻译：
依罗妥珠单抗联合泊马度胺和地塞米松治疗 daratumumab 难治性多发性骨髓瘤的 II 期试验
更新日期：2024-09-05
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-09-05 , DOI: 10.1038/s41408-024-01134-3 Ricardo D Parrondo 1 , Betsy R LaPlant 2 , Jamie Elliott 1 , Andre Fernandez 1 , Caitlin J Flott 1 , Diedre Arrington 1 , Dustin Chapin 1 , Jade Brown 1 , Saurav Das 1 , Vivek Roy 1 , Asher A Chanan-Khan 1, 3 , Sikander Ailawadhi 1, 3
Affiliation
|
中文翻译：
依罗妥珠单抗联合泊马度胺和地塞米松治疗 daratumumab 难治性多发性骨髓瘤的 II 期试验
京公网安备 11010802027423号